• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[核仁组成区(AgNOR)在脑胶质瘤中的价值]

[Value of the nucleolar organizers (AgNOR) in brain gliomas].

作者信息

Ducrot P, Joundi A, Diebold M D, Pluot M

机构信息

Laboratoire Central d'Anatomie, Centre Hospitalier Régional et Universitaire, Hôpital Robert-Debré, Reims.

出版信息

Arch Anat Cytol Pathol. 1991;39(3):88-93.

PMID:1929577
Abstract

The aim of the study was to evaluate the feasibility and possible contribution of silver stained nucleolar organizer regions (AgNORs) to prognostic considerations, in a series of 55 supratentorial gliomas: eight grade II astrocytomas, twelve grade III astrocytomas, thirty grade IV astrocytomas, two glioblastomas, one anaplastic oligodendroglioma, one oligodendroglioma and one ependymoma. Silver NORs (AgNORs) were demonstrated according to the method of Crocker et al. A difference between AgNOR sizes in peritumor and tumor tissue is noted. The mean NOR numbers in the tumor areas range from 0.871 to 2.677, without overlap between peritumor gliosis and glial tumors. A comparative analysis reveals significant correlations between the mean NOR number per nucleus and histological grading. This technique can play a practical role in the diagnosis and grading of tumors sampled by stereotactic biopsies: a count higher than 0.8 is highly suggestive of malignancy. In addition, the distribution of NORs may be important: intratumoral heterogeneity expresses various degrees of transcriptional activity between different glial tumors of the same grade. This technique provides information about the biological behaviour of glial tumors supplementary to that obtained from growth fraction analysis.

摘要

本研究的目的是评估银染核仁组织区(AgNORs)在55例幕上胶质瘤预后考量中的可行性及可能的贡献,这些胶质瘤包括:8例二级星形细胞瘤、12例三级星形细胞瘤、30例四级星形细胞瘤、2例胶质母细胞瘤、1例间变性少突胶质细胞瘤、1例少突胶质细胞瘤和1例室管膜瘤。根据克罗克等人的方法显示银染核仁组织区(AgNORs)。观察到肿瘤周围组织和肿瘤组织中AgNOR大小存在差异。肿瘤区域的平均核仁组织区数量范围为0.871至2.677,肿瘤周围胶质增生与胶质肿瘤之间无重叠。比较分析显示每个细胞核的平均核仁组织区数量与组织学分级之间存在显著相关性。该技术在立体定向活检所取肿瘤的诊断和分级中可发挥实际作用:计数高于0.8高度提示恶性肿瘤。此外,核仁组织区的分布可能很重要:肿瘤内异质性在同一级别的不同胶质肿瘤之间表现出不同程度的转录活性。该技术提供了关于胶质肿瘤生物学行为的信息,是从生长分数分析中获得的信息的补充。

相似文献

1
[Value of the nucleolar organizers (AgNOR) in brain gliomas].[核仁组成区(AgNOR)在脑胶质瘤中的价值]
Arch Anat Cytol Pathol. 1991;39(3):88-93.
2
Nucleolar organizer regions (AgNORs) in primary and recurrent gliomas. A retrospective study.原发性和复发性胶质瘤中的核仁组成区(AgNORs)。一项回顾性研究。
Zentralbl Pathol. 1994 Mar;140(1):73-81.
3
[The analysis of nuclear organizer regions of astrocytomas with various histologic malignancies].[不同组织学恶性程度星形细胞瘤的核仁组成区分析]
No To Shinkei. 1992 Dec;44(12):1083-6.
4
AgNOR- and PCNA-studies in astrocytomas of the optic nerve.视神经星形细胞瘤的银染核仁组成区相关蛋白及增殖细胞核抗原研究
Zentralbl Pathol. 1994 Mar;140(1):83-7.
5
Nucleolar organizer regions (AgNORs) in astrocytic tumors.星形细胞瘤中的核仁组成区(AgNORs)
Zentralbl Pathol. 1994 Mar;140(1):89-94.
6
Location of nucleolar organizer regions (AgNORs) in the nuclei of astrocytic tumors.星形细胞瘤细胞核中核仁组成区(AgNORs)的定位
Clin Neuropathol. 1995 Jan-Feb;14(1):55-61.
7
Microvessel density in brain tumors.脑肿瘤中的微血管密度
Anticancer Res. 1997 Nov-Dec;17(6D):4747-53.
8
[AGNOR analyses of prostate carcinomas of high and malignancy].
Verh Dtsch Ges Pathol. 1993;77:93-7.
9
Frameless stereotactic-directed tissue sampling during surgery of suspected low-grade gliomas to avoid histological undergrading.在疑似低级别胶质瘤手术期间进行无框架立体定向引导下的组织采样,以避免组织学分级过低。
Minim Invasive Neurosurg. 1998 Dec;41(4):183-6. doi: 10.1055/s-2008-1052038.
10
Argyrophilic nucleolar organiser regions (AgNORs) in breast lesions.乳腺病变中的嗜银核仁组成区(AgNORs)
J Indian Med Assoc. 1997 Sep;95(9):492-4.

引用本文的文献

1
Identification of mitophagy-related genes impacting patient survival in glioma.影响胶质瘤患者生存的线粒体自噬相关基因的鉴定
Discov Oncol. 2025 Feb 9;16(1):140. doi: 10.1007/s12672-025-01916-6.